FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891667372> ?p ?o ?g. }

• W2891667372 endingPage "6" @default.
• W2891667372 startingPage "1" @default.
• W2891667372 abstract "Inflammatory myofibroblastic tumor (IMT) is a rare, indolent spindle cell tumor that typically affects children and young adults.1,2 IMTs occur predominantly in visceral soft tissue and are categorized as an intermediate malignancy because they have a potential for local recurrence but rarely progress to distant metastases.2,3 Approximately 50% of IMTs harbor ALK rearrangements, although gene fusions involving ROS1, NTRK3, and PDGFRβ have also been identified.2,4–6 Previously, the presence of ALK gene fusions has typically been identified using immunohistochemistry7; however, newer techniques such as hybridization capture-based next-generation sequencing (NGS) and NGS-based anchored multiplex polymerase chain reaction (PCR) testing can now be used to detect gene fusions.8–10 The identification of patients with actionable gene fusions is important given the availability of promising therapeutic strategies.2,4Surgical resection is the standard of care for patients with solitary IMT,11 but patients with unresectable or advanced disease have limited treatment options. The current National Comprehensive Cancer Network guidelines for soft tissue sarcoma recommend the use of ALK inhibitors for patients with ALK gene fusions12; however, there are no targeted agents approved specifically for use in fusion-positive IMT. Entrectinib is an investigational, central nervous system (CNS)-active, potent, and selective inhibitor of TRK, ROS1, and ALK.8,13,14 In phase 1 trials, entrectinib demonstrated clinical efficacy in patients with different tumor types harboring NTRK, ROS1, or ALK fusions, regardless of the fusion partner gene.8 A majority of the responses to entrectinib occurred in a rapid and durable manner, and some patients remained on study due to clinical benefit even after experiencing disease progression.8Here, we present 2 patients with fusion-positive IMT (DCTN1-ALK and TFG-ROS1) who were enrolled in the ongoing STARTRK-NG phase 1/1b trial ({type:clinical-trial,attrs:{text:NCT02650401,term_id:NCT02650401}}NCT02650401) and treated with entrectinib. These patients were identified as having targetable gene fusions using 2 diagnostic testing methods, a hybrid capture-based targeted exome sequencing assay and anchored multiplex PCR,15,16 at different stages of a diagnostic testing workflow." @default.
• W2891667372 created "2018-09-27" @default.
• W2891667372 creator A5001610703 @default.
• W2891667372 creator A5016432846 @default.
• W2891667372 creator A5017763514 @default.
• W2891667372 creator A5048062997 @default.
• W2891667372 date "2018-11-01" @default.
• W2891667372 modified "2023-10-16" @default.
• W2891667372 title "Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring <i>ROS1</i> or <i>ALK</i> Gene Fusions" @default.
• W2891667372 cites W1576134248 @default.
• W2891667372 cites W1977118470 @default.
• W2891667372 cites W2068834404 @default.
• W2891667372 cites W2104340741 @default.
• W2891667372 cites W2172208023 @default.
• W2891667372 cites W2194206428 @default.
• W2891667372 cites W223909586 @default.
• W2891667372 cites W2259419843 @default.
• W2891667372 cites W2274032786 @default.
• W2891667372 cites W2287835706 @default.
• W2891667372 cites W2292803562 @default.
• W2891667372 cites W2304533799 @default.
• W2891667372 cites W2461870171 @default.
• W2891667372 cites W2530267675 @default.
• W2891667372 cites W2572335661 @default.
• W2891667372 cites W2580173613 @default.
• W2891667372 cites W2586704604 @default.
• W2891667372 cites W2593603913 @default.
• W2891667372 cites W2613362156 @default.
• W2891667372 cites W2618673731 @default.
• W2891667372 cites W2725623454 @default.
• W2891667372 cites W2748209653 @default.
• W2891667372 cites W2755495128 @default.
• W2891667372 cites W2759298856 @default.
• W2891667372 cites W2767549343 @default.
• W2891667372 cites W291132436 @default.
• W2891667372 cites W4285097283 @default.
• W2891667372 cites W4361773613 @default.
• W2891667372 cites W4376848385 @default.
• W2891667372 doi "https://doi.org/10.1200/po.18.00095" @default.
• W2891667372 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6874363" @default.
• W2891667372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33134769" @default.
• W2891667372 hasPublicationYear "2018" @default.
• W2891667372 type Work @default.
• W2891667372 sameAs 2891667372 @default.
• W2891667372 citedByCount "9" @default.
• W2891667372 countsByYear W28916673722020 @default.
• W2891667372 countsByYear W28916673722021 @default.
• W2891667372 countsByYear W28916673722022 @default.
• W2891667372 countsByYear W28916673722023 @default.
• W2891667372 crossrefType "journal-article" @default.
• W2891667372 hasAuthorship W2891667372A5001610703 @default.
• W2891667372 hasAuthorship W2891667372A5016432846 @default.
• W2891667372 hasAuthorship W2891667372A5017763514 @default.
• W2891667372 hasAuthorship W2891667372A5048062997 @default.
• W2891667372 hasBestOaLocation W28916673722 @default.
• W2891667372 hasConcept C104317684 @default.
• W2891667372 hasConcept C111829193 @default.
• W2891667372 hasConcept C121608353 @default.
• W2891667372 hasConcept C126322002 @default.
• W2891667372 hasConcept C142724271 @default.
• W2891667372 hasConcept C2775999482 @default.
• W2891667372 hasConcept C2781182431 @default.
• W2891667372 hasConcept C502942594 @default.
• W2891667372 hasConcept C54355233 @default.
• W2891667372 hasConcept C71924100 @default.
• W2891667372 hasConcept C86803240 @default.
• W2891667372 hasConceptScore W2891667372C104317684 @default.
• W2891667372 hasConceptScore W2891667372C111829193 @default.
• W2891667372 hasConceptScore W2891667372C121608353 @default.
• W2891667372 hasConceptScore W2891667372C126322002 @default.
• W2891667372 hasConceptScore W2891667372C142724271 @default.
• W2891667372 hasConceptScore W2891667372C2775999482 @default.
• W2891667372 hasConceptScore W2891667372C2781182431 @default.
• W2891667372 hasConceptScore W2891667372C502942594 @default.
• W2891667372 hasConceptScore W2891667372C54355233 @default.
• W2891667372 hasConceptScore W2891667372C71924100 @default.
• W2891667372 hasConceptScore W2891667372C86803240 @default.
• W2891667372 hasIssue "2" @default.
• W2891667372 hasLocation W28916673721 @default.
• W2891667372 hasLocation W28916673722 @default.
• W2891667372 hasOpenAccess W2891667372 @default.
• W2891667372 hasPrimaryLocation W28916673721 @default.
• W2891667372 hasRelatedWork W2004137755 @default.
• W2891667372 hasRelatedWork W2103447891 @default.
• W2891667372 hasRelatedWork W2108851944 @default.
• W2891667372 hasRelatedWork W2235388618 @default.
• W2891667372 hasRelatedWork W2752189410 @default.
• W2891667372 hasRelatedWork W2885292615 @default.
• W2891667372 hasRelatedWork W2920428174 @default.
• W2891667372 hasRelatedWork W3001249325 @default.
• W2891667372 hasRelatedWork W3115657223 @default.
• W2891667372 hasRelatedWork W3166448679 @default.
• W2891667372 isParatext "false" @default.
• W2891667372 isRetracted "false" @default.
• W2891667372 magId "2891667372" @default.
• W2891667372 workType "article" @default.